Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 2
2001 1
2005 1
2006 1
2007 2
2008 1
2011 1
2012 1
2013 1
2017 2
2018 1
2020 1
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.
Hanna PE, Strohbehn IA, Moreno D, Harden D, Seethapathy R, Sawtell R, Wang Q, Ouyang T, Katz-Agranov N, Dinulos J, Wander SA, Gupta S, Sise ME. Hanna PE, et al. NPJ Breast Cancer. 2023 Aug 19;9(1):70. doi: 10.1038/s41523-023-00576-5. NPJ Breast Cancer. 2023. PMID: 37598278 Free PMC article.
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated g …
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients wit …
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. Logan JE, et al. Anticancer Res. 2013 Aug;33(8):2997-3004. Anticancer Res. 2013. PMID: 23898052
BACKGROUND: PD-0332991 is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and was evaluated to determine its anti-proliferative effects in 25 renal cell carcinoma (RCC) cell lines. ...
BACKGROUND: PD-0332991 is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and was evaluated to determine its anti-prol …
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH. Martínez-Chávez A, et al. Pharmacol Res. 2022 Apr;178:105954. doi: 10.1016/j.phrs.2021.105954. Epub 2021 Oct 23. Pharmacol Res. 2022. PMID: 34700018
Abemaciclib is the third cyclin-dependent kinase (CDK) 4/6 inhibitor approved for the treatment of breast cancer and currently under investigation for other malignancies, including brain cancer. ...
Abemaciclib is the third cyclin-dependent kinase (CDK) 4/6 inhibitor approved for the treatment of breast cancer and currently …
Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma.
Zhao T, Wang C, Huo X, He ML, Chen J. Zhao T, et al. J Cell Mol Med. 2020 Nov;24(21):12525-12536. doi: 10.1111/jcmm.15795. Epub 2020 Oct 13. J Cell Mol Med. 2020. PMID: 33047871 Free PMC article.
Our results showed that PTE enhanced sorafenib's inhibitory effects on cell viability. The obvious down-regulation of cyclin D1, Cdk-2, Cdk-4, Cdk-6 and p62 and the up-regulation of LC3II, caspase-9, caspase-3 and PARP cleavages were observed for the combination tre …
Our results showed that PTE enhanced sorafenib's inhibitory effects on cell viability. The obvious down-regulation of cyclin D1, Cdk-2, C …
Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment.
Pagels AA, Söderkvist BK, Medin C, Hylander B, Heiwe S. Pagels AA, et al. Health Qual Life Outcomes. 2012 Jun 18;10:71. doi: 10.1186/1477-7525-10-71. Health Qual Life Outcomes. 2012. PMID: 22710013 Free PMC article.
OBJECTIVES: To evaluate health-related quality of life (HRQoL) in patients in different stages of chronic kidney disease (CKD) up to initiation of dialysis treatment and to explore possible correlating and influencing factors. ...Patients in CKD stages 2-3 showed significa …
OBJECTIVES: To evaluate health-related quality of life (HRQoL) in patients in different stages of chronic kidney disease (CKD) up to …
Ribociclib induced acute kidney injury: A case report.
Gulturk I, Yilmaz M, Ozmen A, Tacar SY, Erdal GS, Tural D. Gulturk I, et al. J Oncol Pharm Pract. 2021 Dec;27(8):2023-2026. doi: 10.1177/10781552211007202. Epub 2021 Apr 13. J Oncol Pharm Pract. 2021. PMID: 33847193
Combination of the cyclin D-cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine therapy significantly improves overall survival and progression-free survival. Ribociclib is an oral CDK 4/6 inhibitor and some adverse effects are identified. According to MONA …
Combination of the cyclin D-cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine therapy significantly improves overall survival and …
TGF-beta1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation.
Schoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB. Schoecklmann HO, et al. Kidney Int. 1997 Apr;51(4):1228-36. doi: 10.1038/ki.1997.168. Kidney Int. 1997. PMID: 9083291 Free article.
PDGF stimulation of MCs induced protein expression of the G1 phase cyclin D1 as well as the cyclin-dependent kinases cdk 4 and cdk 2. This was not significantly altered when MCs were coincubated with both, PDGF and TGF-beta1. ...
PDGF stimulation of MCs induced protein expression of the G1 phase cyclin D1 as well as the cyclin-dependent kinases cdk 4 and …
Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review.
Badran O, Abu Amna M, Turgeman I, Bar-Sela G. Badran O, et al. Breast Cancer (Dove Med Press). 2023 Jan 24;15:47-50. doi: 10.2147/BCTT.S380485. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 36718280 Free PMC article.
Cyclin-dependent kinase (CDK) 4/6 inhibitors given with endocrine therapy are standard of care for the treatment of women with advanced hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER-2) negative breast cancer. Ribociclib is a CDK …
Cyclin-dependent kinase (CDK) 4/6 inhibitors given with endocrine therapy are standard of care for the treatment of women with …
An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors.
Hamada T, Akahane T, Yokoyama S, Higa N, Kirishima M, Matsuo K, Shimokawa M, Yoshimoto K, Tanimoto A. Hamada T, et al. Sci Rep. 2022 Jan 24;12(1):1275. doi: 10.1038/s41598-022-05391-9. Sci Rep. 2022. PMID: 35075231 Free PMC article.
Here, the mutation c.1403A > G in exon 10 of the platelet-derived growth factor receptor-alpha (PDGFRA) gene, a VUS found in adult glioblastoma multiforme (GBM), was introduced in human embryonal kidney 293 T (HEK293T) cells using genome editing to investigate its poten …
Here, the mutation c.1403A > G in exon 10 of the platelet-derived growth factor receptor-alpha (PDGFRA) gene, a VUS found in adult gliobl …
Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A, Hofman J, Kučera R, Staud F, Ceckova M. Sorf A, et al. Biochem Pharmacol. 2018 Aug;154:10-17. doi: 10.1016/j.bcp.2018.04.013. Epub 2018 Apr 16. Biochem Pharmacol. 2018. PMID: 29673999
Ribociclib is a novel cyclin-dependent kinase (CDK) 4 and 6 selective inhibitor that recently gained breakthrough therapy status and global approval for advanced breast cancer treatment. ...
Ribociclib is a novel cyclin-dependent kinase (CDK) 4 and 6 selective inhibitor that recently gained breakthrough therapy stat …
20 results